Martinelli Mauro, Glielmo Aldo, Licci Maria Rita, Romanello Daniele
Department of Internal Medicine, San Pietro Fatebenefratelli Hospital, Rome, Lazio 00189, Italy.
Independent Researcher, Rome, Lazio 00100, Italy.
Bladder (San Franc). 2025 Aug 1;12(3):e21200054. doi: 10.14440/bladder.2025.0002. eCollection 2025.
Bladder pain syndrome (BPS), also known as interstitial cystitis, is a chronic condition characterized by pelvic pain and urinary symptoms that severely impair patients' quality of life (QoL). The current therapeutic options often yield suboptimal results, prompting interest in complementary treatments. Systemic ozone therapy, known for its anti-inflammatory, immunomodulatory, and analgesic effects, may represent a promising adjunctive treatment for BPS.
This study aimed to evaluate the efficacy and safety of systemic ozone therapy in improving the self-perceived QoL in patients with BPS.
The retrospective observational study included 40 patients diagnosed with BPS according to ESSIC criteria. All patients underwent systemic ozone therapy administered through hemotransfusion, following a standardized protocol. Outcomes were assessed using the Short Form (SF)-36 questionnaire for QoL and the Global Response Assessment (GRA) for subjective treatment efficacy. Statistical analyses evaluated changes in SF-36 domain scores and their correlation with GRA results.
Patients demonstrated significant improvement across all domains of the SF-36 questionnaire, with the most notable gains observed in physical functioning and mental health. The mean GRA score confirmed patient-perceived effectiveness, showing a strong positive correlation with SF-36 improvements (p<0.05). No adverse events or complications were found during the study.
Systemic ozone therapy appears to be a safe and effective complementary treatment for BPS, significantly enhancing patients' QoL across multiple domains. While these findings are promising, randomized controlled trials are needed to validate the results and further explore underlying mechanisms, such as the role of ozone in modulating inflammatory and neural pathways.
膀胱疼痛综合征（BPS），也称为间质性膀胱炎，是一种慢性疾病，其特征为盆腔疼痛和泌尿系统症状，严重损害患者的生活质量（QoL）。目前的治疗选择往往效果欠佳，这促使人们对辅助治疗产生兴趣。全身臭氧疗法以其抗炎、免疫调节和镇痛作用而闻名，可能是一种有前景的BPS辅助治疗方法。
本研究旨在评估全身臭氧疗法改善BPS患者自我感知生活质量的疗效和安全性。
这项回顾性观察性研究纳入了40例根据ESSIC标准诊断为BPS的患者。所有患者均按照标准化方案通过血液输注接受全身臭氧疗法。使用简短形式（SF）-36生活质量问卷和整体反应评估（GRA）来评估主观治疗效果。统计分析评估了SF-36领域得分的变化及其与GRA结果的相关性。
患者在SF-36问卷的所有领域均有显著改善，其中身体功能和心理健康方面的改善最为明显。平均GRA评分证实了患者感知的有效性，与SF-36的改善呈强正相关（p<0.05）。研究期间未发现不良事件或并发症。
全身臭氧疗法似乎是一种安全有效的BPS辅助治疗方法，可在多个领域显著提高患者的生活质量。虽然这些发现很有前景，但需要进行随机对照试验来验证结果，并进一步探索潜在机制，如臭氧在调节炎症和神经通路中的作用。
